公开(公告)号：US20210213009A1

公开(公告)日：2021-07-15

申请号：US17121305

申请日：2020-12-14

Applicant: Xenon Pharmaceuticals Inc.

Inventor： James Philip JOHNSON, JR. ,  Gregory N. BEATCH

IPC: A61K31/472 ,  A61K9/00 ,  A61P23/00

Abstract: In certain embodiments, the present disclosure is directed to methods for treating pain in a subject, such as a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the subject in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20220062266A1

公开(公告)日：2022-03-03

申请号：US17449785

申请日：2021-10-01

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Gregory N. BEATCH

IPC: A61K31/472 ,  A61K9/00 ,  A61P25/08

Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20210147363A1

公开(公告)日：2021-05-20

申请号：US17069386

申请日：2020-10-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert BICHLER ,  Jean-Jacques Alexandre CADIEUX ,  Matthew David TANDY ,  Gregory N. BEATCH

IPC: C07D217/04

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

公开(公告)号：US20220064120A1

公开(公告)日：2022-03-03

申请号：US17368766

申请日：2021-07-06

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert BICHLER ,  Jean-Jacques Alexandre CADIEUX ,  Matthew David TANDY ,  Gregory N. BEATCH

IPC: C07D217/04

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

公开(公告)号：US20210161886A1

公开(公告)日：2021-06-03

申请号：US17093183

申请日：2020-11-09

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Cynthia Louise HARDEN ,  Gregory N. BEATCH

IPC: A61K31/472 ,  A61P25/24 ,  A61K9/00

Abstract: In certain embodiments, the present disclosure is directed to methods for treating depressive disorders in a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.